In this study there was evaluated the possibility to perform one-stage reconstructive and plastic operations (RPO) in III stage breast cancer (BC) cases. There were analyzed two similar groups of patients, depending on the volume of the operations: in the 1st (main) group there were carried out RPO of different kinds of simultaneously with radical mastectomies (RME), in the 2nd (control) RMEs with preservation of pectoral muscles. There were analyzed overall survival (OS), disease-free survival (DFS); the frequency ofpostoperative complications and aesthetic results of the treatment. 3-, 5- and 10-year OS and DFS in group statistically did not differed significantly (p > 0.05). The rate of postoperative complications was in the group of patients who undergone RPO by TRAM-flap accounted of 8.3%, in the RME group - 6.9% (p> 0.05). The aesthetic results of the treatment: satisfactory in RPO, unsatisfactory - in RME.

The most serious complication of breast cancer (BC), which affects life expectancy, is metastasis of the tumor. Metastasis is the cause of more than 80% of all breast cancer deaths. After surgical treatment and the use of adjuvant therapy, metastases occur in 8% 15% of cases. This indicates the need to develop markers for the prognosis of metastasis and clarify its mechanisms for the creation of anti-metastatic therapeutic agents. In this paper, we studied the association of LOX and uPAR gene expression with breast cancer metastasis in the lymph nodes. Gene expression was measured using real-time PCR in 40 paired samples (tumor-normal tissues). As a result of processing the measurements, the values of gene expression levels in the tumor tissue relative to normal were obtained. It is shown that the LOX gene is expressed in the tumor both lower and higher relative to the norm, and uPAR is expressed in most cases higher. In metastatic tumors, the frequency of expression increases above the norm for both LOX and uPAR genes. The association of expression of these genes with lymphatic metastasis was found: p = 0.01 and p = 0.02, for the LOX and uPAR genes, respectively. The relative risk (RR) was for the LOX gene RR = 1.9, 95% CI 1.2 3, p = 0.005, for uPAR RR = 3.6, 95% CI 1.2 10.9, p = 0.03. Thus, the data obtained contribute to understanding the mechanisms of metastasis and provide the basis for the development of new biomarkers. The LOX and uPAR genes may be candidates for predictive markers of breast cancer metastasis risk.

A serious complication of breast cancer is metastasis of tumor cells. The initiation of this process takes place in the nearby lymphatic vessels. To date, the molecular mechanisms of metastasis are not well understood and further research is required. In this regard, the level of miRNA expression can provide information both on the mechanisms of metastasis development and also be a source of markers for the prognosis of metastatic breast cancer. In the present work, according to the literature, we selected four microRNAs (miR-34a, miR-145, miR-125b and miR-222), potentially capable of being associated with metastasis, to study their association with metastasis to lymph nodes at an early stage. The measurement of the expression of four selected miRNAs on 40 paired samples (tumor-norm) was performed using real-time PCR. Frequencies of miR-34a, miR-145, miR-125b, and miR-222 relative to normal tissue were determined for reduced or increased miR-mRNA expression. For a more detailed study of the association of miRNA expression with lymph node metastasis, miR-125b and miR-222 were selected. An association of expression of these two miRNAs was found with the onset of metastasis to the lymph nodes: with the same level of confidence, differences (p = 0.01). Both miRNAs (miR-125b and miR-222) are involved in the metastasis of breast cancer, apparently by influencing the epithelial-mesenchymal transition. They can potentially act as prognostic biomarkers to assess the likelihood of early lymph node metastases in breast cancer.

In recent years there has been strong progress in the treatment of metastatic colorectal cancer (mCRC) patients. The gain of the median of the overall survival (mOS) rate was more than doubled due to the introduction in the clinical practice of new compounds, the work of a multidisciplinary team, the timely registration of the disease progress, prescription of combined chemotherapy in the second line. The article presents the immediate and long-term results of a comparative study carried out on the basis of Oncology Centers, 122 mCRC patients were included, most of these patients - 87(71,3%) had surgery firstly, after that all patients were treated with standard chemotherapy FOLFOX-4 in the first-line treatment and FOLFIRI in the second line treatment, two groups of patients in the first and second lines of treatment received a combination of chemotherapy and targeted agents (bevacizumab, cetuximab), depending on the biological properties of the tumor (RAS-gene mutation status). The following results: metastatic progression-free survival (mPFS) for FOLFOX-4 group accounted for 12.0(±1.2) months; FOLFOX-4 + Bevacizumab - 20.3(±1.2) months, FOLFOX-4 + cetuximab - 22.0(± 2.0) months; mPFS for second-line therapy for FOLFIRI + bevacizumab group amounted to 24.0(± 3.1) months, FOLFIRI + cetuximab 22.5(±2.5) months, FOLFIRI-1 8.0(±2.4) months, FOLFIRI-2 6.4(±2.6) months; mOS for FOLFOX-4 group was 49.5(±2.5) months; FOLFOX-4 + Bevacizumab - 45.8(±2.1) months; FOLFOX-4 + cetuximab - 37.4(± 2.0) months; mOS for second-line therapy for FOLFIRI + bevacizumab group was 37.8(± 2.1) months, FOLFIRI + cetuximab - 31.5(± 2.3) months, FOLFIRI-1 - 26.3(± 1.8) months, FOLFIRI-2 - 26.2(± 1.9) months. The adverse events during the treatment of patients are reported.

No abstract